Clinical Trial Search

Phase 3 N=300 Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Primary: Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4 — 21.23; 41.14 Percentage of Days

Eisai Inc. Results Feb 2016 0.3% serious AE View details

Phase 3 N=206 Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Phenylketonuria

Primary: Change in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS) / Adult ADHD Self-Report Scale (ASRS) Total Score From Baseline to Week 13 — -4.9; -9.1…

BioMarin Pharmaceutical Results Feb 2016 1.1% serious AE View details

Phase 3 N=468 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Muscle Spasticity

Primary: Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale — 4.1; 4.1; -0.81; -0.61 Scores on a Scale

Allergan Results Feb 2016 4.1% serious AE View details

Phase 3 N=439 Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Pancreatic Cancer

Primary: To Compare 60-day ≥Grade 3 Pancreatic Complication Rates (Fistula, Leak, and Abscess) as Defined by the MSKCC Surgical Secondary Events System Between Patients Who…

Memorial Sloan Kettering Cancer Center Results Feb 2016 81.1% serious AE View details

Phase 3 N=15 Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients

Hepatitis B · Liver Transplantation

Primary: HBV Recurrence — 0; 0 participants

Instituto Grifols, S.A. Results Feb 2016 20.0% serious AE View details

Phase 3 N=551 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases

Primary: Two-year Overall Survival — 46; 51 percentage of patients

Medical College of Wisconsin Results Feb 2016 4.4% serious AE View details

Phase 3 N=216 Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) — 1.6; -62.5 percent change — p=<0.0001

Sanofi Results Jan 2016 8.8% serious AE View details

Phase 3 N=114 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure

Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…

Amgen Results Jan 2016 29.8% serious AE View details

Phase 3 N=577 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Advanced Liposarcoma or Leiomyosarcoma

Primary: Overall Survival (OS) — 13.73; 13.14 Months

Janssen Research & Development, LLC Results Jan 2016 37.6% serious AE View details

Phase 3 N=309 Effect of Ruboxistaurin on Clinically Significant Macular Edema

Diabetic Macular Edema

Primary: Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48 — 3.4; 2.2 percent of participants — p=0.724

Chromaderm, Inc. Results Jan 2016 22.2% serious AE View details

Phase 3 N=685 Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Diabetic Retinopathy

Primary: Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period — 5.5…

Chromaderm, Inc. Results Jan 2016 44.1% serious AE View details

Phase 3 N=203 Treatment for Completers of the Study B7A-MC-MBCM

Diabetic Retinopathy

Primary: Sustained Moderate Visual Loss (SMVL) — 10 participants

Chromaderm, Inc. Results Jan 2016 28.1% serious AE View details

Phase 3 N=151 An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain

Back Pain Lower Back Chronic

Primary: Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's — 42; 16; 18; 4 participants

Eli Lilly and Company Results Jan 2016 5.3% serious AE View details

Phase 3 N=722 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed Multiple Myeloma · Refractory Multiple Myeloma

Primary: Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC) — 20.6; 14.7 months — p=0.012

Takeda Results Jan 2016 56.5% serious AE View details

Phase 3 N=1,311 Actual Use Trial of Atorvastatin Calcium 10 mg

Hypercholesterolemia

Primary: Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level — 49.7 Percentage of participants

Pfizer's Upjohn has merged with Mylan to form… Results Jan 2016 4.3% serious AE View details